Key facts, as of
As of November 2, 2026, Boston Scientific (BSX) trades at $44.12, down 56.2% over the past year. Its 52-week range runs from $39.57 to $105.65; the price is 58.2% below that high. It is 59.7% below its all-time high of $109.50, reached in September 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +90.8%, against +316.3% for the S&P 500 (SPY). It sits 21.6% below its 200-day average of $56.29, and its 50-day average is below the 200-day too: a downtrend on both averages. Its 30-day volatility is 35.9% annualized, which we rate high risk. It has a trailing P/E of 18.6.
Cite: Portfolio Terminal, "Boston Scientific (BSX) stock analysis", 2026-11-02. https://portfolio-terminal.com/analyse/bsx
Where it trades today
trading 7% of the way up its 52-week range
How the price has moved
How far it is from its record
Boston Scientific (BSX) is 59.7% below its all-time high of $109.50, reached in September 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +90.8%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- BSX closes below its 50-day average ($44.67), and the 50-day sits below the 200-day ($56.29): on both averages the chart reads as a downtrend.
- At $44.12, BSX is 58.2% below its 1-year high of $105.65, set on November 13, 2025, and 11.5% above its 1-year low of $39.57 (October 28, 2026).
- Over the past month BSX rose 3.6%, from $42.60 to $44.12.
- BSX trades at 18.6x its last twelve months of earnings and 14.0x the next twelve months' estimate, so analysts expect earnings 32.7% higher.
- Its P/E is 54.5% below the 40.9x median of the 3 other medical devices companies we track (ABT, SYK, EW).
- BSX's 30-day volatility, 35.9% a year, works out to a typical daily move of about 2.3%.
- Yahoo Finance puts its beta at 0.58: over five years of monthly returns, BSX moved about 0.58% for each 1% move of the S&P 500.
What would change the read
- A close above the 50-day average, $44.67 (+1.2%), would turn the read to a rebound; an uptrend also needs the 50-day to climb 26.0% to cross the 200-day at $56.29.
- A close above $105.65 (+139.5%) would be a new 1-year high; below $39.57 (−10.3%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for BSX, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under medical devices among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for BSX by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for BSX. Last refresh: Nov 2, 2026, 7:10 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Medical Devices.
What Boston Scientific does
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological…
Employees
59,000
Industry
Medical Devices
Headquarters
Marlborough, United States
What analysts expect
BSX carries a buy consensus from 28 analysts, with an average price target of $50.03 versus $44.12 today (+13.4%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BSX generated $21.07B in trailing revenue (1.4% year over year), with a 16.6% net margin, against $12.09B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $20.07B | $13.85B | $3.97B | $2.90B | $1.96 | $3.40B |
| 2024 | $16.75B | $11.49B | $3.00B | $1.85B | $1.26 | $2.37B |
| 2023 | $14.24B | $9.89B | $2.42B | $1.59B | $1.08 | $1.70B |
| 2022 | $12.68B | $8.73B | $2.03B | $698.00M | $0.45 | $914.00M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
BSX is in 17 of the 54 ETFs we track. It weighs most in XLV: 1.00% of the fund, holding #25 of 62.
Famous investors who hold it
BSX is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.14% of the portfolio, position #152 of 2,931, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
BSX beside the other companies Yahoo Finance files under medical devices among the assets we track (ABT, SYK, EW, largest first).
BSXyou are here$44.12$63.94B
ABTAbbott Laboratories$110.11$190.53B
SYKStryker Corporation$305.71$116.38B
EWEdwards Lifesciences$92.44$53.28BWhat the chart is saying
In a downtrend, with $42.49 the next floor.
downtrend- Price is 1.2% below its 50-day average and 21.6% below its 200-day.
- RSI at 50 is neither stretched nor washed out.
- The nearest ceiling is $46.09 (+4.5%), the nearest floor $42.49 (-3.7%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is BSX valued right now?
Boston Scientific trades at 18.6 times its last twelve months of earnings and 14.0 times the next twelve months' estimate (Yahoo Finance, November 2, 2026). On the chart: in a downtrend, with $42.49 the next floor. Price is 1.2% below its 50-day average and 21.6% below its 200-day.
What is the risk level of BSX?
Based on 30-day volatility of 35.9%, BSX has HIGH risk. Its beta of 0.58 means it has swung less than the S&P 500 over the last five years.
Does BSX pay dividends?
Yahoo Finance shows no dividend yield for Boston Scientific (November 2, 2026).
How far is BSX from its all-time high?
Boston Scientific is 59.7% below its all-time high of $109.50, reached in September 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +90.8%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold BSX?
17 of the 54 popular ETFs we track hold Boston Scientific. The largest weights: XLV (1.00%), VO (0.31%), VTV (0.24%), RSP (0.20%) and SPYG (0.12%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is BSX?
0.10%, as of September 30, 2026: BSX is holding #180 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.96 in Boston Scientific.
Which famous investors own BSX?
Renaissance Technologies (0.14% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for BSX?
The average analyst price target for Boston Scientific (BSX) is $50.03 based on 28 analyst estimates, about 13.4% above the current price of $44.12. The published range runs from $41.00 to $65.00.
How much revenue does BSX generate?
Boston Scientific reported $21.07B in trailing twelve-month revenue. Revenue growth is running at 1.4% year over year. Net margin sits at 16.6%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare BSX with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.